Update on the taxoids and other new agents in head and neck cancer therapy

Both paclitaxel and docetaxel have shown activity when used as a single agent in patients with squamous cell carcinoma of the head and neck (SCCHN). Combinations of both drugs with platinum derivatives and antimetabolites have been tested in patient populations with encouraging results, but some have exhibited considerable toxicity. It is unknown as yet whether such combinations are in any way superior to the standard platinum-based regimens. Intensive weekly schemes of taxoids and platinum compounds alone or in combination seem possible and deserve further study. Other agents such as vinorelbine, ifosfamide, thymetaq, trimetrexate, gemcitabine and topotecan showed variable activity in patients with SCCHN, but their role is still questionable. Following the optimistic view on the role of chemoradiation, combinations of paclitaxel (with or without carboplatin) with radiotherapy were studied, and the results seem feasible and promising.